These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15974908)

  • 21. Glucocorticoid receptor activation induces decrease of hippocampal astrocyte number in rats.
    Lou YX; Li J; Wang ZZ; Xia CY; Chen NH
    Psychopharmacology (Berl); 2018 Sep; 235(9):2529-2540. PubMed ID: 30069586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antioxidants for the treatment of mild cognitive impairment.
    Mecocci P; Mariani E; Cornacchiola V; Polidori MC
    Neurol Res; 2004 Jul; 26(5):598-602. PubMed ID: 15265281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antiglucocorticoid action of mifepristone.
    Agarwai MK
    Pharmacol Ther; 1996; 70(3):183-213. PubMed ID: 8888066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mifepristone blocks specific glucocorticoid receptor binding in rabbit iris-ciliary body.
    Munden PM; Schmidt TJ
    Arch Ophthalmol; 1992 May; 110(5):703-5. PubMed ID: 1580850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.
    Block T; Petrides G; Kushner H; Kalin N; Belanoff J; Schatzberg A
    J Clin Psychopharmacol; 2017 Oct; 37(5):505-511. PubMed ID: 28708736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mifepristone: treatment of Cushing's syndrome.
    Sartor O; Cutler GB
    Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resetting the Stress System with a Mifepristone Challenge.
    Dalm S; Karssen AM; Meijer OC; Belanoff JK; de Kloet ER
    Cell Mol Neurobiol; 2019 May; 39(4):503-522. PubMed ID: 30173378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drugs in the medical treatment of Cushing's syndrome--an update on mifepristone and pasireotide.
    Schteingart DE
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):279-83. PubMed ID: 22533823
    [No Abstract]   [Full Text] [Related]  

  • 29. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
    Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
    Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity.
    van Haarst AD; Oitzl MS; Workel JO; de Kloet ER
    Endocrinology; 1996 Nov; 137(11):4935-43. PubMed ID: 8895366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGS-742 Novartis.
    Bullock R
    Curr Opin Investig Drugs; 2005 Jan; 6(1):108-13. PubMed ID: 15675610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.
    Nihalani ND; Schwartz TL
    Curr Opin Investig Drugs; 2007 Jul; 8(7):563-9. PubMed ID: 17659476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.
    Young AH; Gallagher P; Watson S; Del-Estal D; Owen BM; Ferrier IN
    Neuropsychopharmacology; 2004 Aug; 29(8):1538-45. PubMed ID: 15127079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion.
    Peeters BW; Tonnaer JA; Groen MB; Broekkamp CL; van der Voort HA; Schoonen WG; Smets RJ; Vanderheyden PM; Gebhard R; Ruigt GS
    Stress; 2004 Dec; 7(4):233-41. PubMed ID: 16019588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of glucocorticoid receptor antagonist on CAPs threshold shift due to short-term sound exposure in guinea pigs.
    Mori T; Fujimura K; Yoshida M; Suzuki H
    Auris Nasus Larynx; 2004 Dec; 31(4):395-9. PubMed ID: 15571913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential hypothalamic arginine vasopressin response to glucocorticoid receptor antagonism in lean and obese Zucker rats.
    Pesonen U; Jolkkonen J; Huupponen R; Koulu M
    Neuroendocrinology; 1992 Aug; 56(2):271-7. PubMed ID: 1407382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
    Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.